Natural history of multiple sclerosis: Implications for counselling and therapy

Current Opinion in Neurology

Volumn 15, Issue 3, 2002, Pages 257-266

  Confavreux, Christian ^a   Vukusic, Sandra ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SEX HORMONE;

DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COUNSELING; PREGNANCY; RELAPSE; REVIEW; VACCINATION;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNIZATION; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PATIENT EDUCATION; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE;

EID: 0036267059     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200206000-00006     Document Type: Review

References (59)

1. The prognosis value of age, gender, pregnancy and endocrine factors in multiple sclerosis
2. Rate of pregnancy-related relapse in multiple sclerosis
3. Pregnancy and multiple sclerosis (the PRIMS study): Two-year results
4. Female sex hormones at supraphysiologic, but not physiologic, levels decrease EAE severity in female SJL mice
5. Exogenous androgen treatment decreases the severity of EAE in SJL male mice
6. Relationship between sex hormones and MRI activity in relapsing-remitting multiple sclerosis
7. Prognostic factors in multiple sclerosis: Role of intercurrent infections and vaccinations against influenza and hepatitis B
8. First demyelinating episode of the central nervous system and hepatitis B vaccination: A pilot case-control study
9. Hepatitis B vaccination and the risk of multiple sclerosis
10. No increase in demyelinating diseases after hepatitis B vaccination
11. School-based hepatitis B vaccination programme and adolescent multiple sclerosis
12. Vaccinations and the risk of relapse in multiple sclerosis
13. Influenza vaccination in MS: Absence of T-cell response against white matter proteins
14. Multiple sclerosis: Epidemiology, genetics, classification, natural history, and clinical outcome measures
15. Concurrent validity of the MS functional composite using MRI as a biological disease marker
16. Optimizing the association between disability and biological markers in MS
17. Multiple sclerosis in Australia: Prognostic factors
18. Short-term prognosis in early relapsing-remitting multiple sclerosis
19. Early onset multiple sclerosis
20. Disability and prognosis in multiple sclerosis: Demographic and clinical variables important for the ability to walk and awarding of disability pension
21. A prospective study on the prognosis of multiple sclerosis
22. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis
23. HLA-DR15 is associated with lower age at onset of multiple sclerosis
24. HLA-DRB1 and disease outcome in multiple sclerosis
25. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis
26. Association of the APOE-E4 allele with disease activity in multiple sclerosis
27. APOE genotype is a major predictor of long-term progression of disability in MS
28. Apolipoprotein E E4 is associated with rapid progression of multiple sclerosis
29. Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis
30. 14-3-3 Protein in the CSF as prognostic marker in early multiple sclerosis
31. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: The role of a follow-up MRI
32. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
33. Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis
34. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis
35. Usefulness of Bayesian graphical models for early prediction of disease progression in multiple sclerosis
36. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis
37. Progressive cerebral atrophy in multiple sclerosis: A serial MRI study
38. Spinal cord atrophy and disability in multiple sclerosis: A new reproducible and sensitive MRI method with potential to monitor disease progression
39. A magnetization transfer histogram study of normal-appearing brain tissue in MS
40. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations
41. Magnetic resonance spectroscopy: Imaging axonal damage in MS
42. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis
43. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
44. Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI
45. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis
46. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
47. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H
48. Relapses and progression of disability in multiple sclerosis
49. How to participate in a multiple sclerosis clinical trial
50. Multiple sclerosis: The importance of early recognition and treatment
51. Multiple sclerosis
52. Defining the clinical course of multiple sclerosis: Results of an international survey
53. The natural history of multiple sclerosis: A geographically based study: 5. The clinical features and natural history of primary progressive multiple sclerosis
54. The natural history of multiple sclerosis: A geographically based study: 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: A re-evaluation
55. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
56. Relapses, progression, inflammation and neurodegeneration in multiple sclerosis: A changing view
57. New cells from old
58. Olfactory ensheathing cells promote locomotor recovery after delayed transplantation into transected spinal cord
59. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis